Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dice Therapeutics Inc
(NQ:
DICE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dice Therapeutics Inc
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
September 01, 2023
Via
Investor Brand Network
Exposures
Product Safety
Why These 3 Large Caps Are Bucking the August Slump
August 22, 2023
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Fossil Fuels
Interest Rates
US Equities
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
July 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
July 10, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
June 21, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
June 21, 2023
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer.
Via
MarketBeat
Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments
June 20, 2023
Via
Spotlight Growth
DICE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DICE Therapeutics, Inc. Is Fair to Shareholders
June 20, 2023
From
Halper Sadeh LLC
Via
Business Wire
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
June 13, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 23, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 15, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
March 01, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics to Participate at Upcoming Investor Conferences
February 08, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
November 09, 2022
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics to Present at Upcoming Investor Conferences
November 03, 2022
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 17, 2022
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Announces Pricing of Upsized Public Offering of Common Stock
October 12, 2022
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Announces Proposed Public Offering of Common Stock
October 11, 2022
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
October 11, 2022
From
DICE Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.